{"title":"Prognostic Relationship Between the Cachexia Index and Osteopenia in Patients With Pancreatic Cancer.","authors":"Teruhisa Sakamoto, Mikiya Kishino, Yuki Murakami, Kozo Miyatani, Yuji Shishido, Kyoichi Kihara, Tomoyuki Matsunaga, Manabu Yamamoto, Naruo Tokuyasu, Yoshiyuki Fujiwara","doi":"10.21873/anticanres.17509","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aim: </strong>The cachexia index (CXI) is a novel biomarker for cancer cachexia. Osteopenia is defined as low bone mineral density (BMD), which is closely associated with cancer cachexia. Osteopenia has received recent attention because of its association with survival outcomes in cancer. The aim of this study was to investigate the relationship between the CXI and BMD in combination as a prognosticator in patients with pancreatic cancer.</p><p><strong>Patients and methods: </strong>This study included 121 patients who had undergone pancreatectomy for pancreatic cancer. Data were retrospectively analyzed to evaluate the prognostic relationship between the CXI and BMD.</p><p><strong>Results: </strong>Five-year overall survival in the high CXI group was significantly better than that in the low CXI group (<i>p</i>= 0.004). Additionally, patients with osteopenia (<i>i.e.</i>, low BMD) had significantly worse 5-year overall survival rates than patients without osteopenia (<i>p</i>=0.026). Multivariate analysis revealed that the CXI was an independent prognostic factor for patients with pancreatic cancer (<i>p</i>=0.020). Regarding the combination of the CXI and osteopenia, patients with both low CXI and osteopenia had a worse prognosis compared with patients with other combinations of the CXI and osteopenia (<i>p</i>=0.007). The area under the curve of the combination of the CXI and BMD to predict 5-year overall survival was greater than those of the CXI or BMD alone.</p><p><strong>Conclusion: </strong>There is a close prognostic relationship between the CXI and osteopenia in patients with pancreatic cancer, and patients with both a low CXI and osteopenia have low survival rates.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 3","pages":"1225-1231"},"PeriodicalIF":1.6000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17509","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background/aim: The cachexia index (CXI) is a novel biomarker for cancer cachexia. Osteopenia is defined as low bone mineral density (BMD), which is closely associated with cancer cachexia. Osteopenia has received recent attention because of its association with survival outcomes in cancer. The aim of this study was to investigate the relationship between the CXI and BMD in combination as a prognosticator in patients with pancreatic cancer.
Patients and methods: This study included 121 patients who had undergone pancreatectomy for pancreatic cancer. Data were retrospectively analyzed to evaluate the prognostic relationship between the CXI and BMD.
Results: Five-year overall survival in the high CXI group was significantly better than that in the low CXI group (p= 0.004). Additionally, patients with osteopenia (i.e., low BMD) had significantly worse 5-year overall survival rates than patients without osteopenia (p=0.026). Multivariate analysis revealed that the CXI was an independent prognostic factor for patients with pancreatic cancer (p=0.020). Regarding the combination of the CXI and osteopenia, patients with both low CXI and osteopenia had a worse prognosis compared with patients with other combinations of the CXI and osteopenia (p=0.007). The area under the curve of the combination of the CXI and BMD to predict 5-year overall survival was greater than those of the CXI or BMD alone.
Conclusion: There is a close prognostic relationship between the CXI and osteopenia in patients with pancreatic cancer, and patients with both a low CXI and osteopenia have low survival rates.
期刊介绍：
ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed.
ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies).
Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
